Actelion submits FDA NDA for selexipag (Uptravi) in patients with PAH
Actelion announced that it has submitted a New Drug Application to the US FDA seeking approval for selexipag (Uptravi®) for the treatment of patients with pulmonary arterial hypertension. Selexipag was studied in the pivotal Phase III GRIPHON study in 1,156 patients with PAH. December 23, 2014